Eli Lilly’s next chapter hinges on whether it can keep up with soaring demand for its obesity and diabetes medicines while scaling production and pushing new treatments through its pipeline. The big question is whether pricing and reimbursement pushback—or dependence on a handful of blockbuster drugs—catches up before its new launches and global expansion do.Read more